| Name | Title | Contact Details |
|---|
BenefitBump is a company of caring and collaborative professionals that remove the stress and confusion of navigating benefits from new parents and expanding families.
Solera is changing lives by guiding people to better health solutions that work. Solera`s value-based technology platform enables successful interventions that address the most prevalent and costly chronic conditions. Solera matches consumers to their best-fit solution within carefully curated networks of digital and community-based point solutions and drives superior engagement and outcomes by managing performance. Solera`s technology platform serves payers and employers by streamlining, integrating, and creating accountability in the point solution ecosystem.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
DocuMed is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MacConnell Research Corp. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.